Skip to main content
Premium Trial:

Request an Annual Quote

With Revenues and Losses Up, Luminex Sets Date for Report on Corporate Assessment

NEW YORK, Oct. 21 (GenomeWeb News) - Luminex today reported an increase in third-quarter revenue and widened net loss.

 

The company also said it plans to release results of a strategic assessment of the business on Dec. 8.

 

"We are working hard to create a focused business, and one better suited to generate long-term shareholder value," Patrick Balthrop, president and CEO, said in a statement.

 

Revenue for the three months ended Sept. 30 increased to $8.4 million from $7.1 million year over year. The Austin, Texas-based molecular biology tools company recorded $4.3 million of revenue from the sale of 177 Luminex systems and $2.1 million from consumables.

 

R&D spending also increased, to $900,000 in the third quarter from $700,000 in the year-ago period.

 

Net loss widened to $1.2 million for the period, or $.04 per share, from $800,000, or $.03 per share, year over year.

 

Luminex said it had around $36.3 million in cash and equivalents.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.